Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2016.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 81030032. A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
